DECLARE–TIMI, the EMPA-REG OUTCOME trial (2015), and the EMPA-REG OUTCOME (2018) all reported an increased risk of SGLT2-i induced infection [25,35,39]. The gene discussed is SLC5A2; the disease is infection.